Latest News-CliniExpert

IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) May 26, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

GAITHERSBURG, Md., May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announce

AstraZeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine

21 May 2020 -- AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the Un

Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)

WALTHAM, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a Ne

Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

NEW YORK, NY / ACCESSWIRE / May 21, 2020 / -- Kadmon Holdings, Inc. (NYSE:KDMN) today announced positive topline results from the primary analysis of ROCKstar (KD025-213), the pivotal trial evaluating

New Longer-Term Data Reinforce Safety of Genentech’s Satralizumab in Adults and Adolescents With Neuromyelitis Optica Spectrum Disorder (NMOSD)

South San Francisco, CA -- May 21, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new pooled pivotal satralizumab safety results for the treatment of neuromy

INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

PLYMOUTH MEETING, Pa., May 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutr

Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--May 20, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced positive topline resul

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generat

Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

BEERSE, Belgium--(BUSINESS WIRE) May 18, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results reported for the first time from a Phase 1 first-in-human dose es

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

RARITAN, N.J., May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab

FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection

December 21, 2020 -- The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and ch